Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Vafidemstat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ORYZON Bolsters Vafidemstat Patents With U.S. Notice Of Allowance
    ORYZON Bolsters Vafidemstat Patents With U.S. Notice Of Allowance

    25 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/25/3262123/0/en/ORYZON-Strengthens-Vafidemstat-Patent-Portfolio-With-U-S-Notice-of-Allowance.html

    GLOBENEWSWIRE
    25 Mar 2026
    Share Share
    ORYZON Granted New Patent For Vafidemstat In Japan
    ORYZON Granted New Patent For Vafidemstat In Japan

    02 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/02/3230223/0/en/ORYZON-Strengthens-Patent-Portfolio-for-Vafidemstat-With-New-Decision-to-Grant-in-Japan.html

    GLOBENEWSWIRE
    02 Feb 2026
    Share Share
    Oryzon Gets FDA Feedback on Ph3 Borderline Protocol
    Oryzon Gets FDA Feedback on Ph3 Borderline Protocol

    17 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/17/3168803/0/en/ORYZON-Receives-Feedback-From-the-FDA-in-Response-to-the-Submitted-Phase-III-Protocol-in-Borderline-Personality-Disorder.html

    GLOBENEWSWIRE
    17 Oct 2025
    Share Share
    Oryzon Bolsters Patent Portfolio for Iadademstat and Vafidemstat
    Oryzon Bolsters Patent Portfolio for Iadademstat and Vafidemstat

    16 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/16/3150714/0/en/ORYZON-Strengthens-Patent-Portfolio-for-Iadademstat-and-Vafidemstat-with-New-Decisions-to-Grant.html

    GLOBENEWSWIRE
    16 Sep 2025
    Share Share
    ORYZON Bolsters Vafidemstat Patent Portfolio
    ORYZON Bolsters Vafidemstat Patent Portfolio

    14 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/14/3114679/0/en/ORYZON-Continues-to-Strengthen-its-Patent-Portfolio-for-Vafidemstat.html

    GLOBENEWSWIRE
    14 Jul 2025
    Share Share
    Oryzon Strengthens Patent Portfolio for Vafidemstat
    Oryzon Strengthens Patent Portfolio for Vafidemstat

    21 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/21/3064596/0/en/ORYZON-Continues-to-Strengthen-its-Patent-Portfolio-for-Vafidemstat.html

    GLOBENEWSWIRE
    21 Apr 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.